Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?
FIVE BURROUGHS WELLCOME AZT PATENTS UPHELD ON APPEAL; SIXTH IS REMANDED TO LOWER COURT FOR FURTHER PROCEEDINGS: NOVOPHARM WILL PRESS ON WITH LITIGATION
Five of Burroughs Wellcome's six patents for AZT (Retrovir, zidovudine) are valid, the D.C. federal appeals court ruled Nov. 22. The three-judge panel reviewed a July 1993 New Bern, N.C. federal court ruling that Wellcome was the sole inventor of AZT. The defendants in the New Bern case, Barr and Novopharm, claimed that the National Institutes of Health should also have been named as an inventor. "On the facts before us, it is apparent that the district court correctly ruled against Barr and Novopharm as to five of the patents" (numbers 4,724,232, 4,828,838, 4,833,130, 4,837,208 and 4,818,538), the appeals court said.
More from Archive
• By
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
• By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
• By
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
• By
Ensitrelvir, Shionogi's treatment for COVID-19, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
• By
AbbVie didn’t get everything it sought from a citizen petition but may still have the upper hand over smaller rivals after FDA gives makers of animal-derived thyroid medications a year to seek approval. If the agency removes compounded products, it could face more pricing pushback.
• By
The findings are consistent with some other research and likely are due to obesity patients becoming more connected to needed health care services.